Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
3 Candidiasis Treatment: An Evolutionary Journey from Past to Present and…
antibiotics. In a similar way, allergens containing foods should be avoided since
they compromise immune function, making it easier for infections to invade
(Martins etal. 2014). Vegetables, legumes, whole grains, and protein sources like
sh, meat, and organic poultry are all free of limitations and can be consumed without any obstacles (Eggimann etal. 2003). Additionally, it is advised to regularly
consume oat bran and/or axseed for their antifungal properties as well as their
ber-rich content (Gul etal. 2016).
67
3.2.2 Strengthening theImmune System
The immune system is weakened (usually depressed) in most chronic candidiasis
cases, which allows Candida species to proliferate easily (Truss 1981; Martins etal.
2014). Restoring proper immune function is therefore one of the main objectives in
the treatment of chronic candidiasis. The management of stress, restricted diet,
exercise, glandular therapy, nutritional supplementation, and the use of plant-based
medications are some strategies that could be employed to accomplish this goal.
Particularly, improving the thymus gland function is essential as clinical remission
of candidiasis is directly reliant on T-cell function (Chotprakaikiat 2016; Bappy
etal. 2023). Therefore, nutritional supplementation is required to guarantee an adequate intake of antioxidants, including carotenes, vitamin A, vitamin E, zinc, and
selenium. Plants like Glycyrrhiza glabra, Hydrastis canadensis, and Echinacea
angustifolia could be added to this intervention (Truss 1981; Shahar etal. 1995; de
Wet etal. 1999; McGirt and Martins 2004).
3.2.3 Toxification
Liver damage is a common cause of both the chronic fatigue and chronic candidiasis
because it severely impairs immunological function when the liver is harmed by
chemicals and other factors. Therefore, to maximize the chances of a successful
therapy for candidiasis, enhanced liver function is crucial prior to, during, and even
following antiyeast treatments (Martins etal. 2014; Manik and Bahl 2017). Liver
function improvement and detoxication can be achieved through with provided
suggestion mentioned in Table3.1.
3.2.4 Alternative Treatments
To treat the infection, natural antiyeast medicines that have been shown to be
effective against Candida spp. can be used in addition to conventional therapies
(Galgóczy etal. 2019; Rodrigues etal. 2019). However, predisposing factors to
chronic candidiasis, nutrition, and lifestyle should also be considered for this
therapy to be effective as a main treatment. The most researched natural agents
against Candida spp. include probiotics, garlic, caprylic acid, tea tree oil,
68
Table 3.1 A list of liver function improvement and detoxication process (Barker 2007; Fife
2017; Manik and Bahl 2017; Ganea 2021)
Procedures
Improve liver
function
Improve
detoxication
1. Prioritize cruciferous vegetables like broccoli, Brussels sprouts, and leafy
greens. These are rich in antioxidants and phytonutrients that aid your liver’s
detoxication process
2. Limit alcohol intake. Excessive consumption strains your liver, so drink
moderately or abstain completely
3. Exercise on most days. Regular physical activity reduces liver fat and
inammation
4. To reduce toxin exposure, avoid harmful substances such as excess
medications and environmental pollutants
1. Focus on ber-rich fruits, vegetables, and whole grains
2. Limit your intake of processed foods, sugary beverages, and unhealthy
fats
3. Maintain adequate hydration throughout the day
4. Get regular exercise to increase circulation and sweating
5. Get enough sleep to help your liver detoxify properly
6. Meditation, yoga, and relaxation techniques can all help you manage
stress
7. Consider incorporating prebiotics and probiotics to improve gut health
8. Consider liver-supportive herbs such as milk thistle or dandelion root
(consult a doctor rst)
9. Reduce your exposure to toxins from cleaning products, cosmetics, and
the environment
M. N. I. Bappy et al.
berberine-containing plants, grape fruit seed extract, and enteric coated volatile
oil preparations containing oregano, thyme, peppermint, and rosemary; propolis; ginger; and cinnamon (Cardoso etal. 2012; Irfana and Selvam 2019; Bappy
etal. 2023). Natural agents used as alternative treatments against candidiasis is
given in Table3.2. Using an efcient antiyeast therapy frequently results in the
quick removal of microorganisms and subsequent absorption of a substantial
amount of yeast toxins, cell particles, and antigens and the Herxheimer reaction.
The aforementioned reaction can be avoided by promoting liver function, following dietary guidelines, and starting antiyeast drugs at low doses and gradually increasing the doses (Murray and Pizzorno 1998; McGirt and Martins 2004;
Martins etal. 2014).
3 Candidiasis Treatment: An Evolutionary Journey from Past to Present and…
Table 3.2 List of natural agents used as alternative treatments against candidiasis
Name Dosage/description
Substances Fiber supplement Guar gum, pectin, or psyllium seeds (one
teaspoon before bedtime)
Formulated multivitamin
and mineral complex
with high potency
Selenium 200 g/day
Zinc picolinate 45mg/day
Probiotics (intestinal
ora)
Caprylic acid Formula of slow liberation (1g with meals)
Phytocompound Citrus paradise
(grapefruit) seed extract
Origanum vulgare
(oregano) oil
Allium sativum (garlic) Actual recommendations are based on allin
Berberis vulgaris
(barberry)
Tabebuia impetiginosa
(lapacho)
Hydrastis canadensis
(goldenseal)
Collected from Manik and Bahl (2017)
Hypoallergenic formulas, free of yeasts
Products containing Lactobacillus
200mg, 2–3 times/day
To avoid digestive discomfort, take 300–500mg
in capsule or liquid form three times per day
with meals
(10mg) and allicin (4000 µg), which is
equivalent to 4000mg fresh garlic or
500–1000mg aged garlic
The following doses, three times/day
Dried bark of the root (as tea): 1–2g
Tincture (1:5): 4–6mL
Liquid extract (1:1): 0.5–2mL
Powdered solid extract (4:1): 250–500mg
15–20g of bark in 0.5L boiling water for
5–15min, 3–4 times/day
The following doses, three times/day
Dried root (as tea): 1–2g
Tincture (1:5): 4–6mL (1–1 and teaspoon)
Liquid extract (1:1): 0.5–2mL
Powdered solid extract (4:1): 250–500mg
69
3.3 Prophylaxis, Preemptive, andEmpirical Therapies
Invasive candidiasis has long been acknowledged as an important clinical phenomenon, especially in critically ill ICU patients, with crude death rates ranging from
40% to 60% (Playford etal. 2010; Soulountsi etal. 2021). Because of this, during the
past 10years, early antifungal medications have been provided to nonneutropenic
adults who were admitted to the intensive care unit (ICU) for a variety of reasons
corresponding to preventive, preemptive, or empirical therapy. While the implementation of early antifungal intervention measures in patients with minimal risk of invasive candidiasis may lead to better clinical results, it may also increase costs, cause
toxicity, and put pressure on ecological selection for antifungal resistance. Therefore,
in order to maximize benets and reduce harms, it is necessary to consider the signicant and competing clinical and nancial impacts of the various techniques.
70
M. N. I. Bappy et al.
3.3.1 Prophylaxis
The administration of antifungal medications to patients who have risk factors for
invasive candidiasis but do not exhibit any clinical infection signs and symptoms is
commonly referred to as prophylaxis (Standaert-Vitse etal. 2006; Jawhara et al.
2008; Rüping etal. 2008). Even though the idea originated almost 40years ago,
clinical practice still faces many challenges with it. Even with many studies, it is
still difcult to identify critically ill patients who need prophylaxis, or to decide
which medication to use, when to start using it, how much to use, how long to use
it, or what kind of monitoring is ideal for this procedure (Martins etal. 2014). There
are no clear denitions of the target population or durations of prophylaxis, and the
current IDSA guidelines only recommend the use of uconazole or echinocandins
in risky individuals in ICUs with high rates of invasive candidiasis (5%) rather than
offering any specic recommendations (Martin 1999).
3.3.2 Preemptive Therapies
Treatment that is started in response to one or more biological indicators of infection risk is known as preemptive therapy. In the context of invasive candidiasis,
these biomarkers could be fungal antigens like (1,3)-b--glucan or Candida colonization parameters (Cornu etal. 2018; Dupuis etal. 2021). Thus, prophylactic therapy and preemptive therapy are paradigms that conceptually overlap, especially
when one applies Candida colonization parameters. Some authors refer to treated
patients as having received empirical therapy, while others refer to preemptive or
presumptive therapy, which has led to confusion regarding the concept of preemptive strategy. Apart from differences in terminology, there is a lack of clarity regarding the methods for identifying the target population, despite suggestions to use
biomarkers to direct prescriptions (Chi etal. 2011).
3.3.3 Empirical Therapies
A balanced approach between appropriateness (of dosage and range of activity) and
timing is required for empirical therapy. It has been demonstrated that early intervention lowers mortality, which is a treatment goal (Espinel-Ingroff 1998; Lee etal.
2000). To establish criteria for starting empirical antifungal therapy in critically ill
nonneutropenic patients, more research is required. In patients with risk factors for
invasive candidiasis and no other known cause of fever, empirical treatment is typically considered based on clinical evaluation of factors associated with risk, serological indicators for invasive candidiasis, and/or culture results obtained from
nonsterile sites. With between 45% and 65% of all prescriptions in European ICUs
going toward early antifungal therapy, there is growing concern about whether or
not toxicity, cost, and resistance development warnings are being disregarded (Lee
etal. 2000; Parslow and Thornton 2022).
3 Candidiasis Treatment: An Evolutionary Journey from Past to Present and…
71
3.4 Therapeutic Approach
In invasive Candida species infections, the most often employed antifungal agents
are azoles, polyenes, and echinocandins. Individual isolates do not always follow
the general pattern of Candida susceptibility to newly developed antifungal agents
(Nguyen etal. 1998; Pfaller etal. 1998; Diekema etal. 2002) For example, Candida
albicans is usually vulnerable to all major agents. However, azole resistance in this
species is now well documented in those infected with HIV with frequent oropharyngeal candidiasis (Mulu etal. 2013), and it has also been identied in critically ill
adults with invasive candidiasis (Powderly etal. 1999; Hamza et al. 2008). As a
result, vulnerability testing for resistance to azole medications is increasingly being
employed to direct candidiasis treatment in patients, particularly while the initial
treatment with empirical agents fails. New insights have signicantly altered therapeutic strategies in recent years.
3.4.1 Azoles
Azoles are a type of antifungal medication that is commonly used as the primary
and most common treatment option for Candida infections (Sobel and Sobel 2018).
In the azole-based family of substances, there are imidazoles (including ketoconazole (KTC), miconazole, econazole, and clotrimazole) and triazoles, which (such
as uconazole, itraconazole, and voriconazole, with voriconazole being an articial
triazole derived of the second-generation uconazole), alongside posaconazole
(which is a hydroxylated analog of itraconazole) (Shukla etal. 2018). These chemicals can be taken orally, have little toxicity, and are successful in relieving symptoms and eliminating Candida cultures in the vast majority of patients. Miconazole
and KTC remained the rst azoles to emerge and were the only medications available for systemic use at the time, with KTC serving as the principal substitute to
AMB (Groll) (Spencer etal. 2023). Triazoles such as itraconazole and FLZ were
then released, offering increased efcacy and tolerability over KTC (Jha etal. 2022).
FLZ is often used in the treatment of candidemia as a deescalation strategy, as
well as in the management of noncritically ill patients who have never been exposed
to azoles and have no evidence of azole-resistant strain colonization (Pristov and
Ghannoum 2019). Its broad use in the treatment of Candida infections can be
ascribed to its low toxicity and availability in a variety of formulations (Spampinato
and Leonardi 2013). Nonetheless, ndings in the literature have emphasized the
emergence of resistance, particularly in Candida species and their azole response.
This highlights the necessity of studying fungal resistance mechanisms in order to
create novel types of antifungal drugs for treating Candida infections.
Itraconazole is known for its efcacy against mucosal candidiasis and, when
administered intravenously, can treat invasive illness (Martin 1999). Although itraconazole is believed to have a similar prole to FLZ, the two substances have distinct pharmacological properties and clinical activity against various fungal
infections.
72
M. N. I. Bappy et al.
Voriconazole is available in both oral and parenteral formulations and is equally
effective as FLZ in treating esophageal candidiasis (Vazquez 2010). However, current research has linked voriconazole to an increased risk of adverse effects. Notably,
voriconazole has been shown to be effective against FLZ-resistant isolates (Pelletier
etal. 2002). Furthermore, several azoles now in development, such as posaconazole
and ravuconazole, show promise anti-Candida action invitro (Gowda etal. 2019).
3.4.1.1 Mode ofAction
Azoles primarily interact by interfering with ergosterol formation, which is an
essential component of the fungal cell exterior (Nigam 2015). This method of action
is unique to fungi because ergosterol has a structural homolog in human cells, cholesterol. Azoles impede ergosterol synthesis, causing structural alterations in fungal
cell membranes and, ultimately, cell death (Haller 1985; Francois et al. 2006;
Bondaryk etal. 2013).
One of the enzymatic processes in the ergosterol biosynthesis pathway is the
conversion of lanosterol to ergosterol. FLZ, itraconazole, and KTC are azoles that
inhibit the enzyme lanosterol 14-demethylase by attaching to an iron-containing
heme group. This enzyme is essential for lanosterol demethylation, which allows it
to proceed down the ergosterol production pathway (Bossche and Marichal 1991).
When azoles inhibit the activity of lanosterol 14-demethylase, several important
effects occur within the fungal cell:
Toxic Intermediate Accumulation Inhibiting the enzyme lanosterol
14- demethylase hinders the conversion of lanosterol to ergosterol. As a result, a
substance known as 14-methyl-3,6-diol accumulates within the fungal cell. This
chemical is poisonous to fungal cells.
Membrane Destabilization The fungal cell membrane becomes structurally
unstable when it lacks ergosterol. Ergosterol is required for membrane integrity and
uidity. Without it, the membrane is more prone to injury and permeability
variations.
Enhanced Membrane Permeability Changes in membrane composition caused
by ergosterol biosynthesis disruption result in enhanced permeability. This increased
permeability permits cellular contents to leak, destroys the cell’s capacity to maintain osmotic equilibrium, and leads to cellular failure.
Fungistatic and Fungicidal Effects Azoles have fungistatic properties, which
means they limit the growth and replication of Candida species. However, under
some conditions, such as prolonged exposure or increased medication concentrations, they can transform into fungicidal agents, killing the fungal cells directly.
3.4.1.2 Resistance Mechanism toAzole
While azoles are quite effective, resistance can develop over time. Resistance mechanisms include changes in the enzyme lanosterol 14-demethylase, which makes it
3 Candidiasis Treatment: An Evolutionary Journey from Past to Present and…
Fig. 3.1 Mode of action of therapeutics for candidiasis
73
less susceptible to azole inhibition, or increased activity of efux pumps (Fig.3.1),
which remove the drug from the fungal cell (Nigam 2015). Antifungal resistance
emphasizes the signicance of prudent and informed azole use, as well as susceptibility testing in cases of suspected resistance.
3.4.2 Echinocandins
Echinocandins are antifungal drugs that work by preventing the formation of -glucan
in the fungal cell wall by noncompetitively inhibiting the enzyme 1,3-glucan synthase.
Caspofungin, micafungin, and anidulafungin (Pfaller etal. 2008, 2009) are all members of this class. Caspofungin has been shown to be as effective as AMB deoxycholate
and FLZ in the treatment of oropharyngeal and esophageal candidiasis (Arathoon etal.
2002; McCormack and Perry 2005) and is the rst licensed echinocandin antifungal
medication. It is worth noting that, like the other drugs in this category, caspofungin is
only accessible in the parenteral form, and its primary mode of action is limited to
Candida and Aspergillus species. Except for Aspergillus, echinocandins have little
effect against Cryptococcus neoformans or lamentous fungi. This specicity is signicant when considering their use as empirical treatment (Chen etal. 2011).
3.4.2.1 Mode ofAction
Their mechanism of action is intimately related to the chemical structure of the
fungal cell wall, which is primarily composed of a complex sugar known as beta(1,3)--glucan. Caspofungin, micafungin, and anidulafungin are echinocandins that
specically inhibit (1,3)-beta--glucan synthase, the enzyme responsible for the
production of beta-(1,3)--glucan (Chen etal. 2011; Curto etal. 2021).
Echinocandins bind to the enzyme’s active site, preventing it from performing its
critical role in the synthesis of beta(1,3)--glucan. Without the synthesis of beta(1,3)--glucan, the fungal cell cannot successfully develop or repair its cell wall.
74
M. N. I. Bappy et al.
The cell wall weakens and loses structural integrity. The weakened cell wall allows
for greater permeability (Fig.3.1), allowing vital cellular components to leak. This
reduces the fungal cell’s ability to maintain osmotic balance. As a result of continuous structural damage and permeability changes, the fungal cell eventually succumbs to lysis, forcing its contents to spill out and resulting in cell death (Denning
1997; Fera etal. 2009).
3.4.2.2 Resistance toEchinocandins
Resistance to echinocandins can occur through a variety of mechanisms, but it is
uncommon. Mutations in the fungal FKS genes encoding (1,3)-beta--glucan
synthase alter the structure of the enzyme and reduce drug binding afnity. Some
Candida species can also develop resistance to echinocandins by changing the
structure of beta-(1,3)--glucan. Overexpression of efux pumps that expel the
medication, genetic changes in regulatory pathways governing glucan synthesis,
or changes in cell wall composition can all lead to resistance (Perlin 2015; Pristov
and Ghannoum 2019). While echinocandin resistance is less common than resistance to other antifungal classes, understanding these pathways is critical for early
detection and the development of effective treatment strategies when resistance is
expected.
3.4.3 Polyenes
AMB is the most commonly used polyene medication in the treatment of fungal
infections, with other chemicals in the same class including nystatin and natamycin
(Carolus etal. 2020). These medications are not taken orally and are primarily used
to treat fungal infections of the gastrointestinal tract, such as oral thrush. They must
be taken intravenously for systemic fungal infections.
AMB has traditionally been used in its classic deoxycholate formulation.
Three lipid-associated AMB formulations have been developed and licensed for
human use: AMB lipid complex (ABLC), AMB colloidal dispersion (ABCD),
and liposomal AMB (Bolard 1991; Gangadhar etal. 2014). The name of these
substances, combined with the obligation to deliver lipid-associated formulations at substantially greater doses than deoxycholate formulations, has caused
some consternation (Silva etal. 2011). It is critical to understand that (1) “liposomal amphotericin B” refers to a specic lipid-associated product; (2) “lipidassociated formulations of amphotericin B” is a broad term for the class; (3)
these three lipid-associated AMB formulations have distinct pharmacological
properties and rates of treatment-related adverse events and should not be used
3 Candidiasis Treatment: An Evolutionary Journey from Past to Present and…
75
interchangeably without careful consideration; and (4) the typical IV dose for
AMB is 0.6–1.0mg/kg per day; and (5) the typical dosage for the lipid-associated formulations when used for candidiasis is 3–5mg/kg per day (Pappas etal.
2004). While AMB deoxycholate was once the conventional treatment for inva-
sive candidiasis, its toxicity is now generally recognized. Previously, lipid-associated preparations were generally reserved for patients who were unable to
tolerate deoxycholate formulations or had infections that were resistant to them.
3.4.3.1 Mode ofAction
AMB and other polyenes ght Candidiasis by binding to ergosterol, a component of
the fungal cell membrane. This interaction compromises membrane integrity, resulting in the formation of holes and an increase in membrane permeability (Brajtburg
etal. 1990; Zarif etal. 2000). This increased permeability causes critical ion leakage,
impairing the osmotic balance and function of the fungal cell and ultimately leading
to cell death (Fig.3.1) (Carrillo-Munoz etal. 2006). Polyenes are distinct from fungistatic antifungals in that they cause direct cellular damage, making them effective
against a broad range of fungus species, including Candida. Polyene resistance is
possible, but it is less common than resistance to other antifungal medication classes.
3.4.3.2 Resistance toPolyenes
Resistance to polyenes, such as amphotericin B, in the treatment of Candidiasis
can emerge via a variety of routes. Candida species may diminish ergosterol levels
in cell membranes or replace it with other sterols, lowering polyene binding afnity. Improved efux pumps effectively remove the drug from the cell (Fig.3.1),
lowering its concentration, whereas cell wall alterations can make the fungus
more resistant (Carolus etal. 2020). Biolm production and heteroresistance, in
which a subset of cells exhibits resistance, add to the difculties of treating
Candidiasis using polyenes. Understanding these resistance pathways is critical
for effective treatment and creating resistance-ghting tactics (Table3.3).
Numerous new classes of antifungal medicines are currently being developed
as given in Table3.4. These medicines include both those with mechanisms of
action similar to those found in existing therapeutic classes and those with unique
mechanisms of action that are either specic to fungi or have a higher selectivity
for fungal targets when compared to mammalian cells. Many of these medicines
have shown signicant activity in both invitro and in vivo tests against a wide
variety of fungus species. Furthermore, some of these novel antifungal drugs have
shown effectiveness against azole and echinocandin-resistant isolates (Murphy
and Bicanic 2021).
76
Benet/harm
Effective therapy has the
potential to save lives.
Nephrotoxicity caused by
amphotericin B can complicate
the care of critically ill patients
M. N. I. Bappy et al.
Because of the ambiguity of this
illness, medicines with reduced
toxicity are typically
recommended
Ineffective antifungal medication
may have unfavorable
epidemiological repercussions,
such as the selection of resistant
organisms
As part of the initial nonmedical management, all
existing central venous catheters (B-II) should be
removed if possible
The clinical condition of the patient determines which of
these treatments is used
Caspofungin experience is modest (a 70-mg loading
dosage followed by 50mg daily), but clinical activity is
excellent
For clinically stable individuals who have not previously
undergone azole medication (A-I), uconazole (6mg/kg
per day; i.e., 400mg/day for a 70-kg patient) is another
appropriate choice
Treatment options Recommendation
• Intravenous amphotericin B
• Intravenous or oral uconazole
• Intravenous caspofungin
• The combination of uconazole
plusamphotericin B
Name
Candidemia and
acute
hematogenously
disseminated
Table 3.3 A list of treatments options according to the types of candidiasis (Pappas etal. 2004)
candidiasis
A-I suggests a uconazole (800mg/day) and
amphotericin B deoxycholate e (0.7mg/kg per day for
the rst 5–6days) combination
Fluconazole (6–12mg/kg per day) has been used
satisfactorily in a small number of infants
If therapy is administered, it should only be given to
individuals who have (1) Candida species colonization
(ideally at several sites), (2) multiple additional risk
factors, and (3) no other untreated causes of fever (C-III)
The absence of Candida species colonization suggests a
lesser risk of invasive candidiasis and justies deferring
empirical therapy
• Intravenous amphotericin B
• Intravenous/oral uconazole
Empirical treatment
of febrile
nonneutropenic
patients with
suspected
disseminated
candidiasis